4-(2-Bromo-1,2-difluoroethenyl)-1-methoxy-2-nitrobenzene | 824976-13-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-Bromo-1,2-difluoroethenyl)-1-methoxy-2-nitrobenzene
• 英文别名: 4-(2-bromo-1,2-difluoroethenyl)-1-methoxy-2-nitrobenzene
• CAS: 824976-13-8
• 化学式: C9H6BrF2NO3
• 分子量: 294.05
• InChiKey: NXELTXDSVOLWRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Fluorocombretastatin and derivatives thereof
  申请人：Giannini Giuseppe

  公开号：US20060160778A1

  公开（公告）日：2006-07-20

  The present invention is related to new derivatives of Combretastatin, of Formula obtained by total synthesis. The strategy developed for each of the compounds is to i) replace a halogen (i.e. fluorine atom) to hydrogen on olefinic bound; ii) replace an aromatic ring in a natural product with an amino-aromatic ring. Said compounds recognize and bind the tubulin site: are useful for treating pathological states which arise from or are exacerbated by cell proliferation—as anticancer and/or antiangiogenic activity, in a mammal—to pharmaceutical compositions comprising these compounds.

  本发明涉及通过全合成获得的Combretastatin新衍生物，其化学式为。每种化合物的策略是：i）在烯丙基键上用氢替换卤素（即氟原子）；ii）用氨基芳香环替换天然产物中的芳香环。所述化合物识别并结合微管蛋白位点：适用于治疗由细胞增殖引起或加剧的病理状态，作为哺乳动物中的抗癌和/或抗血管生成活性，以及包含这些化合物的制药组合物。
• FLUOROCOMBRETASTATIN AND DERIVATIVES THEREOF
  申请人：SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP2112990A2

  公开（公告）日：2009-11-04
• US7572778B2
  申请人：——

  公开号：US7572778B2

  公开（公告）日：2009-08-11
• [EN] FLUOROCOMBRETASTATIN AND DERIVATIVES THEREOF<br/>[FR] FLUOROCOMBRETASTATINE ET SES DERIVES
  申请人：SIGMA TAU IND FARMACEUTI

  公开号：WO2005007603A2

  公开（公告）日：2005-01-27

  The present invention is related to new derivatives of Combretastatin, of Formula (I) obtained by total synthesis. The strategy developed for each of the compounds is to i) replace a halogen (i.e. fluorine atom) to hydrogen on olefinic bound; ii) replace an aromatic ring in a natural product with an amino-aromatic ring. Said compounds recognize and bind the tubulin site: are useful for treating pathological states which arise from or are exacerbated by cell proliferation - as anticancer and/or antiangiogenic activity, in a mammal - to pharmaceutical compositions comprising these compounds.